Skip to content

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Are Effective COVID Medications Like Ivermectin Being Suppressed Because Their Successful Treatments Could Cause Vaccines to Lose Government Funding?

Show Me

Oops. Pre-Print Study Shows mRNA ‘Vaccinated’ Individuals At Greater Risk For Delta Disease Than Those With Natural Immunity

Show Me

Evacuations resume in Kabul after deadly attacks that killed 100-plus including 13 U.S. troops

Show Me

Rice University Discovers Inaccurate COVID-19 Positive Rate After Delaying In-person Classes

Show Me

Why So Many Jews Vote for Democrats–And How to Change That

Show Me

France: Soldiers, Firemen Must Take Vaccine

Show Me

Judge Sanctions 9 Trump Campaign Attorneys Over Election Lawsuit

Show Me

Democratic Congressional Campaign Committee Chairman Partied Maskless at Billionaire’s Estate in France After State Dept. Issued ‘Do Not Travel’ Warning

Show Me

As COVID Surges Among Fully Vaccinated, CDC Fails to Properly Track Breakthrough Cases

Show Me

Florida doctors urge unvaccinated to get shots: ‘It’s the worst it’s ever been right now’

Show Me

More Than 267,000 Excess Infants Deaths Were Reported Worldwide In 2020 Due To Economic Fallout From COVID-19, Study Suggests

Show Me

While Praising Mask Wearing For Covid-19, The Most Widely Referenced Study By The American Institute of Physics Admits 40% to 54% Of Aerosolized Exhalants Pass Through R95 and KN95 Masks

Show Me

Mosque bomber now identifies as a woman, says right-wing blogs fueled “inner-conflict” leading up to attack

Show Me

Taliban Executed Civilians, Recruited Child Soldiers, UN Rights Chief Warns

Show Me

ACLU Claims South Carolina Ban on School Mask Mandates Violates Rights

Show Me

Virginia Democratic nominee McAuliffe: ‘Make it hard’ for unvaccinated to enter planes, theaters

Show Me

Court Rules Judicial Watch Lawsuit Can Proceed against Colorado Officials to Force Cleanup of State’s Voter Rolls

Show Me

Charlie Watts, the Unlikely Soul of the Rolling Stones

Show Me

Dr. Malone, mRNA Technology Inventor, Discusses Covid-19 mRNA ‘Vaccine’ Adverse Reactions & “The Ultimate Gaslighting” | Video: 4 Minutes 26 Seconds

Show Me

Here Is The Evidence Based Data On A ‘Vaccine’ So Safe Mandates Are Called For Worldwide | The Total Number Of Deaths Reported For the mRNA ‘Vaccine’ Is Greater Than The Number Of Deaths Associated With All Other Vaccines Combined Since 1990

Show Me

Vindication for the Swedish model of non-coercive pandemic mitigation? | Mask-free Sweden had near zero COVID-19 daily deaths in July, fared better than expected economically with no lockdowns in place

Show Me

One Fully Vaccinated. The Other Not. Yet Both In The Hospital. | “Rev. Jesse Jackson and Wife Remain Hospitalized for Covid-19”

Show Me

Freedom at Stake

Show Me

FDA Approves Pfizer Vaccine After CDC Admitted Vaccines Cause ‘Increased Risk Of Severe Disease,’ Evidence Of ‘Waning Vaccine Effectiveness’

Show Me

Americans Are Being Overwhelmed By Dems On Purpose | The Pfizer ‘Vaccine’ Magically Approved Today Because President Joe Biden Said Speed It Up | Video: 2 Minutes 56 Seconds

Show Me

How, Who and Why Election 2020 Was Stolen As Explained By Retired Colonel Phil Waldron, U.S. Army | Video: 22 Minutes 54 Seconds

Show Me

President Donald Trump Rally Full Speech in Cullman, AL 8/21/21 | 1 Hour 35 Minutes 58 Seconds

Show Me

Mike Lindell: It’s Not Trump 2024, It’s Trump 2021! | Video: 1 Minute 3 Seconds

Show Me

Exclusive: FBI finds scant evidence U.S. Capitol attack was coordinated – sources

Show Me

Biden Effect: Taliban Fighters in Suicide Vests March in Zabul Carrying US-Made Weapons – Military Commander in Kabul Shows Off Fleet of US Humvees

Show Me

Judicial Watch: U.S. Capitol Police Tell Federal Court January 6 Disturbance Videos Are Not Public Records

Show Me

She Was Declared a Witch at Salem. These Middle Schoolers Want to Clear Her Name.

Show Me

Minnesota GOP Head Resigns After Sex Trafficking Allegations Against Top Donor

Show Me

‘Unfit to Lead’: Biden Supporters Enraged After Afghanistan Debacle

Show Me

Naval Academy expels 18 midshipmen after finding they cheated on physics exam

Show Me

So Much For ‘Amnesty’: Taliban Going Door-to-Door Executing U.S. Allies

Show Me

Philadelphia Mayor Rejects Calls for National Guard Amid Surge in Murders

Show Me

Miami, Tampa school boards impose mask mandates, in defiance of state law

Show Me

Joe Biden Hopes You’ll Forget His Afghan Incompetence by August 31. No, Seriously. That’s Their Strategy.

Show Me

Dr. Malone, The Inventor Of The mRNA Technology, Explains Why The Covid ‘Vaccine’ Does Not Prevent The Spread Of The Virus | Video: 2 Minutes 14 Seconds

Show Me